5-Amino-1MQ vs SLU-PP-332: Inhibitor versus Agonist in Metabolic Research

Catalogue them side by side and they look like rivals; read their mechanisms and they barely belong in the same conversation. 5-Amino-1MQ shuts an enzyme down. SLU-PP-332 switches a receptor program on. One subtracts, the other adds — and that single inversion of logic is the whole story.

Both compounds appear together in metabolic and mitochondrial research catalogues, which invites a direct comparison. In practice they share almost nothing at the molecular level: they engage different targets, act through opposite logic — enzyme inhibition versus nuclear-receptor activation — and have distinct chemistry. This comparison is framed strictly for in vitro and laboratory research use only (RUO). Nothing here describes human use, dosing, or therapeutic outcomes; all mechanisms are characterised as preclinical cell-culture and animal findings.

What is 5-Amino-1MQ in research terms?

5-Amino-1MQ (5-amino-1-methylquinolinium; CAS 685079-15-6) is a small-molecule, membrane-permeable inhibitor of nicotinamide N-methyltransferase (NNMT). The interest is positional: NNMT consumes both nicotinamide, an NAD+ precursor, and S-adenosylmethionine (SAM), the universal methyl donor, placing the enzyme at the intersection of two cellular budgets — the NAD+ pool and the methylation pool. In high-fat-diet mouse models, selective NNMT inhibitors of this chemotype were reported to reduce adiposity,¹ and genetic NNMT knockdown produced a comparable protective phenotype,² establishing the enzyme as a metabolic-research target. That dual budget is what makes NNMT compelling as a probe: inhibit it, and a researcher is nominally tugging on NAD+ availability and methyl-group flux at once. 5-Amino-1MQ has since become a widely cited chemical probe used to interrogate NNMT across adipocyte-energy, fibrosis, and tumour-stroma models,³⁴⁵ with the enzyme increasingly examined as a regulator in hepatocellular-carcinoma metabolism.¹⁰ The throughline is consistent: NNMT is treated as a node where energy currency and epigenetic substrate meet, and 5-Amino-1MQ is the reagent used to perturb it.

What is SLU-PP-332 in research terms?

SLU-PP-332 (CAS 303760-60-3) is a synthetic pan-agonist of the estrogen-related receptors ERRalpha, ERRbeta and ERRgamma — orphan nuclear receptors that act as transcriptional master switches for oxidative, mitochondria-rich metabolism. By engaging all three ERR isoforms, SLU-PP-332 is studied as an exercise mimetic: in cell and rodent models it induced an ERRalpha-dependent acute aerobic-exercise transcriptional response and altered exercise-capacity and metabolic endpoints,⁶⁷ and the receptor-pharmacology rationale has been reviewed more broadly.⁹ The chemotype continues to be developed, with newer orally characterised ERR agonists such as SLU-PP-915 extending the series.⁸ Where 5-Amino-1MQ removes an enzymatic constraint, SLU-PP-332 recruits a transcriptional program — it does not block a single reaction but biases the cell toward the broad oxidative, mitochondria-rich gene set the ERR receptors govern. Critically, this is an activator of a receptor program, not an enzyme inhibitor, and that distinction propagates through every downstream readout a researcher might design around it.

The comparison collapses to a single contrast: one compound takes a brake off methylation and NAD+ chemistry, the other puts a foot on the mitochondrial accelerator.

How do the two compounds differ side by side?

Side-by-side identity, mechanism and format specifications for the two compounds as supplied for research use.

131 g/mol separate the two molecules — 159.21 for 5-Amino-1MQ against 290.32 for SLU-PP-332 — a reminder that nothing about their chemistry is shared.

Which format suits which research question?

Both compounds are offered in two formats. The lyophilised or powder vial — 5-Amino-1MQ at 10 mg; SLU-PP-332 at 5 mg, DMSO-soluble — suits in vitro work where a defined stock concentration is reconstituted by the investigator. The HPMC capsule format provides a fixed, pre-portioned quantity of reference material per unit, with 5-Amino-1MQ at 50 mg and SLU-PP-332 in 500 mcg and 1 mg research tiers, and no reconstitution. Capsule purity is specified at ≥98% (HPLC) and vial purity at ≥99% (HPLC). Format selection is a handling and study-design choice for the researcher; it does not imply any route of administration, and neither product is intended for human or animal consumption.

Is the evidence clinical or preclinical?

Honest appraisal: the evidence for both compounds is preclinical. The findings cited here come from cell-culture and rodent studies. For 5-Amino-1MQ, the NNMT-inhibition and anti-obesity signals derive from mouse high-fat-diet models¹ and supporting genetic-knockdown work in mice,² with newer reports extending NNMT inhibition into fibrosis and oncology models.³⁴⁵ For SLU-PP-332, the exercise-mimetic and metabolic-syndrome data are from in vitro reporter assays and rodent studies,⁶⁷ with the receptor-pharmacology rationale reviewed more broadly.⁹ Neither compound has established efficacy or safety in humans, and no controlled human clinical trials define a therapeutic role for either. Researchers should treat both strictly as experimental tool compounds.

Because both sit firmly in the preclinical column, reproducibility rests on knowing exactly what is in the vial or capsule. Both are supplied strictly for research use only — not a drug, supplement, food, or cosmetic — and each batch ships with a third-party Certificate of Analysis. Where a study turns on a clean mechanistic readout, that COA and the underlying HPLC and mass-spectrometric identity and purity data are the difference between a result and an artefact.